MA40225A - SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS - Google Patents
SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDSInfo
- Publication number
- MA40225A MA40225A MA040225A MA40225A MA40225A MA 40225 A MA40225 A MA 40225A MA 040225 A MA040225 A MA 040225A MA 40225 A MA40225 A MA 40225A MA 40225 A MA40225 A MA 40225A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- salts
- well
- substituted
- substituted dihydroisoquinolinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule générale (i) dans laquelle r1, r2, r3, r4, l, x et z sont tels que définis ici, ainsi que leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques comprenant ces composés et sels, ainsi que des procédés d'utiliser de tels composés, sels et compositions pour le traitement de la croissance cellulaire anormale, y compris le cancer.The present invention relates to compounds of general formula (i) wherein r1, r2, r3, r4, l, x and z are as defined herein, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising these compounds and salts, as well as as methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013410P | 2014-06-17 | 2014-06-17 | |
| US201562156533P | 2015-05-04 | 2015-05-04 | |
| PCT/IB2015/054272 WO2015193765A1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
| EP15730290.2A EP3157915B1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40225A true MA40225A (en) | 2019-02-27 |
| MA40225B1 MA40225B1 (en) | 2019-05-31 |
Family
ID=53434412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40225A MA40225B1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US9481666B2 (en) |
| EP (2) | EP3157915B1 (en) |
| JP (1) | JP6152495B1 (en) |
| KR (1) | KR101877187B1 (en) |
| CN (1) | CN107207464B (en) |
| AP (1) | AP2016009605A0 (en) |
| AU (1) | AU2015275826B2 (en) |
| BR (1) | BR112016029612B1 (en) |
| CA (1) | CA2894298C (en) |
| CL (1) | CL2016003246A1 (en) |
| CR (2) | CR20160574A (en) |
| CU (1) | CU24408B1 (en) |
| CY (1) | CY1121706T1 (en) |
| DK (1) | DK3157915T3 (en) |
| EA (1) | EA031892B1 (en) |
| ES (1) | ES2721031T3 (en) |
| GE (2) | GEP20186933B (en) |
| HR (1) | HRP20190604T1 (en) |
| HU (1) | HUE042964T2 (en) |
| IL (1) | IL248991B (en) |
| LT (1) | LT3157915T (en) |
| MA (1) | MA40225B1 (en) |
| MD (1) | MD4820C1 (en) |
| ME (1) | ME03419B (en) |
| MX (1) | MX2016016764A (en) |
| MY (1) | MY185765A (en) |
| NZ (1) | NZ726108A (en) |
| PE (1) | PE20161552A1 (en) |
| PH (1) | PH12016502378A1 (en) |
| PL (1) | PL3157915T3 (en) |
| PT (1) | PT3157915T (en) |
| RS (1) | RS58632B1 (en) |
| SG (1) | SG11201609386YA (en) |
| SI (1) | SI3157915T1 (en) |
| SV (1) | SV2016005333A (en) |
| TN (1) | TN2016000529A1 (en) |
| TW (1) | TWI561516B (en) |
| UA (1) | UA118380C2 (en) |
| UY (1) | UY36170A (en) |
| WO (1) | WO2015193765A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111305C2 (en) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Condensed with lactams of aryl and heteroaryl |
| DK3157915T3 (en) | 2014-06-17 | 2019-04-23 | Pfizer | Substituted dihydroisoquinolinone compounds |
| TW201708210A (en) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產（第二）有限公司 | Enhancer of ZESTE homolog 2 inhibitors |
| TW201718598A (en) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
| PE20190106A1 (en) | 2016-05-05 | 2019-01-15 | Glaxosmithkline Ip No 2 Ltd | ZESTE APPROVAL ENHANCER INHIBITORS 2 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| EP3655392A1 (en) | 2017-07-17 | 2020-05-27 | Abbvie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as s1p modulators |
| MX2020004731A (en) | 2017-11-14 | 2020-10-28 | Pfizer | Ezh2 inhibitor combination therapies. |
| EP4043466B1 (en) | 2018-01-31 | 2024-08-21 | Mirati Therapeutics, Inc. | Prc2 inhibitors |
| HRP20240793T1 (en) | 2018-04-18 | 2024-09-13 | Constellation Pharmaceuticals, Inc. | MODULATORS OF METHYL-MODIFYING ENZYMES, THEIR PREPARATIONS AND USE |
| CN112262143A (en) * | 2018-05-21 | 2021-01-22 | 星座制药公司 | Modulators of methyl-modified enzymes, compositions and uses thereof |
| CN112399857A (en) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Inhibition of PRC2 subunits treats ocular disorders |
| EP3870173A4 (en) * | 2018-10-24 | 2022-06-22 | Vanderbilt University | Wdr5 inhibitors and modulators |
| KR102689665B1 (en) * | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | Novel heterotricyclic derivatives and use thereof |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| EP3980422A1 (en) | 2019-06-05 | 2022-04-13 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| PH12022550188A1 (en) | 2019-07-24 | 2022-11-21 | Constellation Pharmaceuticals Inc | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
| WO2022018594A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones |
| AR123185A1 (en) * | 2020-08-10 | 2022-11-09 | Novartis Ag | COMPOUNDS AND COMPOSITIONS TO INHIBIT EZH2 |
| CA3165787C (en) * | 2020-08-13 | 2023-06-06 | Seung Hyun Jung | Novel dioxoloisoquinolinone derivatives and use thereof |
| CN116783188A (en) * | 2020-12-11 | 2023-09-19 | 上海奕拓医药科技有限责任公司 | A kind of dihydroisoquinolinone derivative and its application |
| CN118302427A (en) * | 2021-12-02 | 2024-07-05 | 上海翰森生物医药科技有限公司 | Fused ring derivative regulator, preparation method and application thereof |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| CN116239519A (en) * | 2023-02-20 | 2023-06-09 | 安徽峆一药业股份有限公司 | A kind of synthetic method of (2-benzyloxy-4,6-dimethylpyridin-3-yl)methanol |
| WO2025064641A1 (en) * | 2023-09-19 | 2025-03-27 | Sri International | Synthetic compounds comprising dihydroisoquinolinone monomers |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Cyclodextrin derivatives with increased water solubility and uses thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
| CA2619462A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| AU2006331765A1 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US8569298B2 (en) * | 2008-06-17 | 2013-10-29 | Astrazeneca Ab | Pyridine compounds |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| NZ603454A (en) | 2010-05-07 | 2014-06-27 | Glaxosmithkline Llc | Indoles useful for treating cellular proliferation diseases such as cancer |
| EP2566479B1 (en) | 2010-05-07 | 2014-12-24 | GlaxoSmithKline LLC | Azaindazoles |
| EP2566328B1 (en) | 2010-05-07 | 2015-03-04 | GlaxoSmithKline LLC | Indazoles |
| KR102511807B1 (en) | 2010-09-10 | 2023-03-20 | 에피자임, 인코포레이티드 | Inhibitors of human ezh2, and methods of use thereof |
| US8946260B2 (en) * | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
| TWI598336B (en) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | Substituted benzene compounds |
| BR112014007603A2 (en) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | cancer treatment methods |
| WO2013059944A1 (en) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| CN105452226B (en) | 2012-12-21 | 2017-09-12 | Epizyme股份有限公司 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
| UA111305C2 (en) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Condensed with lactams of aryl and heteroaryl |
| SI2934568T1 (en) | 2012-12-21 | 2018-03-30 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| FR3000059A1 (en) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | COMPOSITION FOR PLASTER PLATES AND PRODUCTS OBTAINED |
| UY35240A (en) | 2012-12-21 | 2014-07-31 | Plexxikon Inc | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND ITS INDICATIONS |
| EA026687B1 (en) | 2012-12-21 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Peptides as oxytocin agonists |
| FR3000065A1 (en) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | BICYCLIC COMPOUNDS HAVING ACTIVITY POTENTIATING THE ACTIVITY OF AN ACTIVE ANTIBIOTIC AGAINST MYCOBACTERIA-PHARMACEUTICAL COMPOSITION AND PRODUCT COMPRISING SUCH COMPOUNDS |
| PT3067358T (en) | 2012-12-21 | 2019-11-18 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| DK3157915T3 (en) | 2014-06-17 | 2019-04-23 | Pfizer | Substituted dihydroisoquinolinone compounds |
-
2015
- 2015-06-05 DK DK15730290.2T patent/DK3157915T3/en active
- 2015-06-05 CU CU2016000180A patent/CU24408B1/en unknown
- 2015-06-05 MA MA40225A patent/MA40225B1/en unknown
- 2015-06-05 EP EP15730290.2A patent/EP3157915B1/en active Active
- 2015-06-05 PT PT15730290T patent/PT3157915T/en unknown
- 2015-06-05 JP JP2016573051A patent/JP6152495B1/en active Active
- 2015-06-05 EP EP19159058.7A patent/EP3521285A1/en not_active Withdrawn
- 2015-06-05 HU HUE15730290A patent/HUE042964T2/en unknown
- 2015-06-05 TN TN2016000529A patent/TN2016000529A1/en unknown
- 2015-06-05 HR HRP20190604TT patent/HRP20190604T1/en unknown
- 2015-06-05 ES ES15730290T patent/ES2721031T3/en active Active
- 2015-06-05 CR CR20160574A patent/CR20160574A/en unknown
- 2015-06-05 PE PE2016002737A patent/PE20161552A1/en unknown
- 2015-06-05 UA UAA201611695A patent/UA118380C2/en unknown
- 2015-06-05 CR CR20200484A patent/CR20200484A/en unknown
- 2015-06-05 RS RS20190512A patent/RS58632B1/en unknown
- 2015-06-05 KR KR1020177001230A patent/KR101877187B1/en active Active
- 2015-06-05 WO PCT/IB2015/054272 patent/WO2015193765A1/en not_active Ceased
- 2015-06-05 PL PL15730290T patent/PL3157915T3/en unknown
- 2015-06-05 GE GEAP201514347A patent/GEP20186933B/en unknown
- 2015-06-05 MD MDA20160136A patent/MD4820C1/en active IP Right Grant
- 2015-06-05 EA EA201692114A patent/EA031892B1/en unknown
- 2015-06-05 CN CN201580032058.7A patent/CN107207464B/en active Active
- 2015-06-05 SI SI201530698T patent/SI3157915T1/en unknown
- 2015-06-05 AU AU2015275826A patent/AU2015275826B2/en active Active
- 2015-06-05 ME MEP-2019-85A patent/ME03419B/en unknown
- 2015-06-05 AP AP2016009605A patent/AP2016009605A0/en unknown
- 2015-06-05 SG SG11201609386YA patent/SG11201609386YA/en unknown
- 2015-06-05 BR BR112016029612-5A patent/BR112016029612B1/en active IP Right Grant
- 2015-06-05 MY MYPI2016704453A patent/MY185765A/en unknown
- 2015-06-05 NZ NZ726108A patent/NZ726108A/en unknown
- 2015-06-05 MX MX2016016764A patent/MX2016016764A/en active IP Right Grant
- 2015-06-05 GE GEAP201814347A patent/GEAP201814347A/en unknown
- 2015-06-05 LT LTEP15730290.2T patent/LT3157915T/en unknown
- 2015-06-15 TW TW104119287A patent/TWI561516B/en active
- 2015-06-16 UY UY0001036170A patent/UY36170A/en not_active Application Discontinuation
- 2015-06-16 CA CA2894298A patent/CA2894298C/en active Active
- 2015-06-16 US US14/740,439 patent/US9481666B2/en active Active
-
2016
- 2016-09-12 US US15/262,230 patent/US20160376254A1/en not_active Abandoned
- 2016-11-15 IL IL248991A patent/IL248991B/en active IP Right Grant
- 2016-11-29 PH PH12016502378A patent/PH12016502378A1/en unknown
- 2016-12-05 SV SV2016005333A patent/SV2016005333A/en unknown
- 2016-12-19 CL CL2016003246A patent/CL2016003246A1/en unknown
-
2017
- 2017-06-28 US US15/635,648 patent/US20170298048A1/en not_active Abandoned
-
2018
- 2018-10-10 US US16/156,304 patent/US10570121B2/en active Active
-
2019
- 2019-04-05 CY CY20191100381T patent/CY1121706T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40225A (en) | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | |
| MA45920A (en) | PYRIDOPYRIMIDINONE CDK2 / 4/6 INHIBITORS | |
| MA52360B1 (en) | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES USED AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | |
| MA40111A1 (en) | Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein | |
| MA42410A (en) | OXYSTEROLS AND THEIR METHODS OF USE | |
| MA44721A (en) | MACROCYCLIC MCL1 INHIBITORS FOR CANCER TREATMENT | |
| MA38175A1 (en) | Lactams fused to an aryl and heteroaryl | |
| MA47079B1 (en) | Amino-triazolopyidin compounds and their use to treat cancer | |
| MA39898B1 (en) | 4-amino-imidazoquinoline compounds | |
| EP4252848A3 (en) | Oxysterols and methods of use thereof | |
| MA37400B1 (en) | Heterocyclyl compounds as mek inhibitors | |
| MA41134A (en) | 5-AMINO-6H-THIAZOLO [4,5-D] PYRIMIDINE-2,7-DIONE SUBSTITUTE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS | |
| MA33745B1 (en) | Alternative pepperdines that increase the activity of p53 and the use of their compounds | |
| WO2019035863A8 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| MA39995B1 (en) | Compounds for treating spinal muscular atrophy | |
| MA37762B1 (en) | N-aryltriazole compounds used as antagonists of lpar | |
| MA39777A (en) | ORGANIC COMPOUNDS OF THE MONOBACTAMS FAMILY FOR THE TREATMENT OF BACTERIAL INFECTIONS | |
| MA40123A1 (en) | Pyrimidines used as factor xia inhibitors | |
| MA37764A1 (en) | N-alkyltriazole compounds used as antagonists of lpar | |
| MA40955A (en) | 2-AMINO-6- (DIFLUOROMETHYL) -5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS | |
| MA35749B1 (en) | Nucleoside derivatives 4'-azido, 3'-fluoro substituted as inhibitors of vhc arn replication | |
| TN2016000188A1 (en) | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | |
| MA38315A1 (en) | Heterocycle-substituted tetracyclic compounds and methods for their use in the treatment of viral diseases | |
| MA40250A (en) | QUINOLIZINONE DERIVATIVES USED AS PI3K INHIBITORS | |
| MA39315A1 (en) | Pyridazine derivatives for use in the prevention or treatment of ataxic disorder |